Compare ACADIA Pharmaceuticals Inc. (ACAD) vs MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs MONDELEZ INTERNATIONAL INC Common Stock — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.78 (market cap $4.49B), while MONDELEZ INTERNATIONAL INC Common Stock trades at $59.82 (market cap $77.30B). The key difference: MONDELEZ INTERNATIONAL INC Common Stock is far larger — about 17.2× ACADIA Pharmaceuticals Inc.'s market cap, and MONDELEZ INTERNATIONAL INC Common Stock pays a 3.32% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | MDLZ | |
|---|---|---|
Market Cap | $4.49B | $77.30B |
Sector | Health | Consumer Staples |
52-Week High | $28.06 | $70.75 |
52-Week Low | $20.06 | $51.51 |
Enterprise Value | $3.69B | $97.40B |
Dividend Yield | — | 3.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
MDLZ trades at $60.22, down 1.13% today, with a bearish technical signal but strong fundamentals including consistent earnings beats and a 75.6% analyst buy rating. Revenue grew to $38.54B in 2025, though net margin compressed to 6.36%. Recent news highlights innovation in brands like Toblerone and Sour Patch Kids, alongside a new CFO appointment and a $0.50 dividend declaration.
Outlook: Wall Street consensus target of $67.86 suggests 12.7% upside, supported by resilient snacking demand and cost management. Risks include cocoa price volatility and competitive pressures, but the stock offers value with a P/E of 29.3 and stable cash flows, positioning it for recovery if technical resistance at $61 is breached.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About MONDELEZ INTERNATIONAL INC Common Stock
Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.
Read more on MDLZ →
